Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.63 |
| ▸ | STAT3 | P40763 | 5/20 | 0.40 |
| ▸ | GRAMD1A | Q96CP6 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31729996 | 0.96 | DDB1 (0.58) | DDB1CRBNSTAT3 | |
| SCHEMBL20840369 | 0.88 | DDB1 (0.52) | DDB1CRBNSTAT3 | |
| SCHEMBL29347427 | 0.87 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL29347426 | 0.85 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL20850806 | 0.85 | CRBN (0.57) | DDB1CRBN | |
| SCHEMBL31730014 | 0.84 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL26098558 | 0.83 | DDB1 (0.59) | DDB1CRBNSTAT3GRAMD1A | |
| SCHEMBL26100785 | 0.83 | DDB1 (0.59) | DDB1CRBNSTAT3GRAMD1A | |
| SCHEMBL26504792 | 0.83 | DDB1 (0.59) | DDB1CRBNSTAT3GRAMD1A | |
| SCHEMBL31553813 | 0.83 | DDB1 (0.58) | DDB1CRBNGRAMD1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4624467-A2 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2019060742-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | DDB1 660/4885CRBN 7/4885STAT3 2529/4885 |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | DDB1 660/4885CRBN 7/4885STAT3 2529/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DDB1 660/4885CRBN 7/4885STAT3 2529/4885 |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | NR2C2, SRR, NCOR2 | DDB1 999/4885CRBN 11/4885STAT3 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.